Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Basiliximab and Pegaspargase in the Treatment of Relapsed/Refractory Extranodal NK/T-cell Lymphoma, Nasal Type: a Single Arm, Open Label, Phase 2 Trial

NCT04337593 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT04337593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04337593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Basiliximab and Pegaspargase in the Treatment of Relapsed/Refractory Extranodal NK/T-cell Lymphoma, Nasal Type: a Single Arm, Open Label, Phase 2 Trial
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2020
Completion date
December 31, 2022
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal nk/t-cell lymphoma